Project profile — Advance Market Commitment for Pneumococcal Vaccines (II)


Advance Market Commitments (44006)
2010-04-13 - 2020-12-31
Global Affairs Canada
MFM Global Issues & Dev.Branch

Country / region 

• Africa, regional (25.00%)
• America, regional (25.00%)
• Asia, regional (25.00%)
• Europe, regional (25.00%)


• Basic Health: Infectious disease control (12250) (100.00%)

Policy marker 

• Gender equality (not targeted)
• Environmental sustainability (cross-cutting) (not targeted)
• Participatory development and good governance (not targeted)
• Trade development (not targeted)
• Biodiversity (not targeted)
• Climate change mitigation (not targeted)
• Climate Change Adaptation (not targeted)
• Urban issues (not targeted)
• Desertification (not targeted)
• Children's issues (not targeted)
• Youth Issues (not targeted)
• Indigenous Issues (not targeted)
• Disability (not targeted)
• ICT as a tool for development (not targeted)


The Advance Market Commitment (AMC) is a financial commitment by multiple donors to help pay for the future purchase of a vaccine for pneumococcal disease, a leading cause of child deaths from pneumonia and meningitis in developing countries. Pneumococcal disease is responsible for more than 1.7 million deaths per year. Of these deaths, almost 90% occur in developing countries, and half occur among children under age five. The AMC is an innovative way to protect the lives of the world’s poorest children by making vaccines available in developing countries more quickly. It is based on the concept of putting money aside to guarantee the purchase of vaccines once they are developed as long as they meet criteria specifically set out for the developing world. It aims to stimulate vaccine makers to accelerate the production of vaccines for developing countries and sell them at prices that poor countries can afford. The AMC is expected to save an estimated 7 million lives by 2030. The total donor commitment to the AMC is US$1.5 billion. These funds allow for the implementation of the AMC concept by the World Bank and the GAVI Alliance. Canada's total commitment to the AMC is US$200 million, of which C$115 million have been disbursed. This project represents the balance of Canada's contribution, which is disbursed based on country demand for pneumococcal vaccines.

Expected results 


Results achieved 

Results achieved by GAVI’s Advance Market Commitment through the support of Canada and other international donors during the period of 2010 to 2012 include: a total of 101 million doses produced and delivered, culminating in an estimated number of over 10 million children in 24 countries immunized against today’s main cause of pneumonia.

Budget and spending 

Original budget $0
Planned disbursement $0
Country percentages by sector
Type of finance Aid grant excluding debt reorganisation
Collaboration type Multilateral
Type of aid Core contributions to multilateral institutions
Date modified: